OBD Stock Overview
A biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Oxford BioDynamics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0061 |
| 52 Week High | UK£0.16 |
| 52 Week Low | UK£0.005 |
| Beta | 0.51 |
| 1 Month Change | -59.47% |
| 3 Month Change | -47.81% |
| 1 Year Change | -95.95% |
| 3 Year Change | -97.90% |
| 5 Year Change | -99.37% |
| Change since IPO | -99.62% |
Recent News & Updates
Recent updates
Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation
Jan 18
Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation
Oct 08Is Oxford BioDynamics (LON:OBD) In A Good Position To Invest In Growth?
Sep 21Oxford BioDynamics (LON:OBD) Is In A Good Position To Deliver On Growth Plans
May 24We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate
Dec 07Shareholder Returns
| OBD | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 1.3% | -0.9% | 1.0% |
| 1Y | -95.9% | -10.5% | 10.4% |
Return vs Industry: OBD underperformed the UK Life Sciences industry which returned -10.5% over the past year.
Return vs Market: OBD underperformed the UK Market which returned 10.4% over the past year.
Price Volatility
| OBD volatility | |
|---|---|
| OBD Average Weekly Movement | 28.7% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: OBD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: OBD's weekly volatility has increased from 19% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 53 | Jon Anthony Burrows | www.oxfordbiodynamics.com |
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.
Oxford BioDynamics Plc Fundamentals Summary
| OBD fundamental statistics | |
|---|---|
| Market cap | UK£1.92m |
| Earnings (TTM) | -UK£11.11m |
| Revenue (TTM) | UK£617.00k |
3.1x
P/S Ratio-0.2x
P/E RatioIs OBD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBD income statement (TTM) | |
|---|---|
| Revenue | UK£617.00k |
| Cost of Revenue | UK£361.00k |
| Gross Profit | UK£256.00k |
| Other Expenses | UK£11.36m |
| Earnings | -UK£11.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 41.49% |
| Net Profit Margin | -1,800.32% |
| Debt/Equity Ratio | 0% |
How did OBD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 01:42 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oxford BioDynamics Plc is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tara Raveendran | Shore Capital Group Ltd |
| null null | Stifel, Equities Research |
| Christian Glennie | Stifel, Equities Research |